Avita Medical received a buy rating reaffirmation from TD Cowen, alongside MarketBeat consensus ratings and SEC insider buying disclosures.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avita Medical received a buy rating reaffirmation from TD Cowen, alongside MarketBeat consensus ratings and SEC insider buying disclosures.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Avita Medical
Australian public company
Nothing else this week.
-
TD Cowen
American investment bank
-
MarketBeat
American personal finance blog
Related events
- MarketBeat published average ratings and price targets for Kalaris Therapeutics, while Citigroup reaffirmed an outperform rating and TD Cowen initiated coverage with a buy rating.
- MarketBeat uses for analyst ratings and competes in the medical device market, involving Teleflex and Vasamed.
- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- Analyst firms Jefferies and TD Cowen upgraded their ratings for Forgent Power Solutions, Inc., while MarketBeat provided consensus data.
- MarketBeat provided consensus ratings and target prices, while Jefferies Financial Group reaffirmed a hold rating on Target Healthcare REIT.